What Is FLGR-242? The Follistatin Analog With No Published Studies

Published November 2026 · Patriot Labs Research Team · ~12 min read

The short answer

FLGR-242 is a supplier designation for a product marketed as a recombinant follistatin analog. It is not a molecule described in the scientific literature, and no study has been published under that name.

That is the single most important thing to know about it, and it is the thing most pages selling it leave out. The compound is real in the sense that vials exist and are shipped; what does not exist is a published characterization of what is in them, or any study that tested it. Searches of PubMed, Europe PMC and ClinicalTrials.gov return nothing for FLGR-242 or FLGR242.

The biology routinely attached to the name belongs to follistatin, a protein with a literature going back to 1987.^[1] The muscle results attached to it mostly come from follistatin gene therapy, which is a different intervention.^[7][8] This guide separates the three: what is claimed, what follistatin biology actually establishes, and what nobody has tested.

A designation, not a molecule

Most research-peptide names describe the thing itself. “Follistatin 344” tells you the residue count of a precursor whose sequence has been published since 1988.^[2] “BPC-157” and “TB-500” point at defined sequences. FLGR-242 does not work this way: it is a brand name introduced in late 2025 by a single commercial source, and the construct behind it has never been deposited, sequenced in a publication, or independently characterized.

This matters for anyone evaluating the material, because the usual checks do not apply. There is no reference standard to compare a certificate of analysis against, no published molecular weight to confirm by mass spectrometry, and no literature sequence to verify. A certificate of analysis can still report purity as a chromatographic area percentage and can still report net peptide content — but “99% pure” answers the question “how much of this powder is one substance”, not “is that substance what the label says”. Identity confirmation requires knowing what the identity should be.

What the manufacturer claims

The company that introduced FLGR-242 describes it as a fragmented and modified form of Follistatin 344, fused through a hydrophilic glycine–serine linker to an albumin-binding construct. Three specific properties are claimed for it. Each is stated here as a claim, because that is what it is.

None of these claims is implausible. All three describe things protein engineers do routinely and can do successfully. The point is narrower and worth stating precisely: a plausible claim that has not been tested is still an untested claim, and a construct that has not been characterized cannot be confirmed to have the properties its designer intended.

The biology it points at

Follistatin is a secreted glycoprotein, isolated in 1987 from porcine ovarian follicular fluid as a single-chain protein of roughly 35 kDa that suppressed follicle-stimulating hormone release from cultured rat pituitary cells — the activity that named it.^[1] The human gene encodes a 344-residue precursor; removing its 29-residue signal sequence gives the mature 315-residue protein.^[2]

Functionally it is a ligand trap. It captures members of the TGF-β superfamily and prevents them reaching their receptors. The 2005 crystal structure of the follistatin–activin complex showed how: two follistatin molecules wrap around one activin dimer and cover the binding surfaces for both the type I and type II receptors, so activin cannot signal.^[3] Follistatin is not a hormone acting on the pituitary; it works by removing the growth factor that would otherwise act.

That trapping is not selective for one ligand, which is the part marketing language tends to skip. Follistatin binds several TGF-β family members, and mice lacking it die shortly after birth with defects across multiple tissues.^[9] Its biology does not reduce to a single pathway.

Myostatin, and where the muscle data comes from

The commercial interest in follistatin runs through myostatin. Myostatin, identified in 1997 as a TGF-β family member, acts as a negative regulator of skeletal muscle mass: mice lacking it are substantially more muscular than normal.^[4] Anything that blocks myostatin therefore attracts attention.

Follistatin is one such blocker. In 2001, Lee and McPherron reported that purified myostatin binds the activin type IIB receptor and that follistatin inhibits that binding. They then generated transgenic mice expressing follistatin under a skeletal-muscle-specific promoter, and those animals showed dramatic increases in muscle mass comparable to myostatin-knockout mice.^[5]

Read that finding precisely, because it is the single study most often stretched. It is a transgenic mouse: an animal genetically engineered so that its own muscle tissue manufactures follistatin continuously, from development onward. It is not a mouse that was given follistatin. The finding establishes that sustained follistatin expression in muscle increases muscle mass in that model. It does not establish what happens when a protein is supplied from outside, in a different species, in an adult animal, over a limited period — and it says nothing at all about a modified construct that did not exist when the study was done.

Why gene-therapy results are not evidence here

The most impressive numbers circulating in FLGR-242 marketing come from follistatin gene therapy. Those studies are real and the work is good. In 2008, Haidet and colleagues reported long-term muscle-mass and strength increases in mice after a single administration of myostatin-inhibitor genes.^[8] In 2009, Kota and colleagues reported that follistatin gene delivery enhanced muscle growth and strength in nonhuman primates.^[7]

Both delivered a gene, packaged in a viral vector, injected into muscle, after which the muscle tissue itself produced follistatin continuously and locally for months or years. That is a structurally different intervention from injecting a protein. The two differ in where the protein appears, how long it persists, what concentration tissue sees, and how the exposure is sustained. A result obtained one way is not a result for the other.

This is not a technicality about study design. It is the difference between a single administration that clears and a tissue that has been reprogrammed to keep producing. Citing the second as evidence for the first inflates the record by a wide margin, and it is the most common way follistatin products are oversold.

The albumin-binding strategy

The one claimed feature of FLGR-242 with a clear literature behind it — in general terms — is the albumin-binding fusion. Serum albumin is the most abundant protein in plasma and has an unusually long circulating lifetime. Attaching a therapeutic protein to something that binds albumin lets it borrow that persistence instead of clearing at its own rate.

Dennis and colleagues laid this out as a general method in 2002, showing that fusing albumin-binding peptides to proteins substantially extended their circulating half-life across several test proteins.^[6] It has since become standard practice. Our guide on peptide half-life extension covers this and the related approaches in more depth.

So the approach is sound and the literature supports it as a technique. What the literature does not contain is any measurement of this construct: no reported half-life, no pharmacokinetic curve, no binding constant. The strategy is established; its application here is unverified.

FLGR-242, FLGR242, FLRG and the typos

Several similar strings circulate, and only one of them names a real protein.

The FLGR / FLRG transposition is the one worth watching, because both appear in discussions of myostatin binding and a reader can swap them without noticing.

What no study has tested

Stated as a list, because the absence is easy to lose in prose. As of November 2026 there is no published:

• structural or analytical characterization of the FLGR-242 construct
• binding measurement against myostatin, activin or heparin
• pharmacokinetic or half-life measurement
• cell-culture or animal study using the material
• clinical trial, case report or registered study under the name
• independent third-party identity confirmation against a reference standard

Every one of those is an ordinary thing to expect for a characterized compound, and Follistatin 344 has most of them. The contrast is the reason this guide exists.

In the laboratory

Material of this kind is supplied as a lyophilized powder. Proteins substantially larger than short synthetic peptides are more sensitive to handling than the catalog average: they are more prone to aggregation, more sensitive to repeated freeze–thaw cycles, and more easily denatured by agitation or by reconstituting too vigorously. Sealed vials are stored refrigerated, protected from light and moisture, and reconstituted solution is kept cold. Our guides on peptide handling and how peptides degrade cover the general principles.

Where a construct is uncharacterized, the usual advice to verify identity before use carries more weight than usual rather than less.

What this guide does not establish

This guide is an educational account of what is and is not known about a commercial designation. Its limits are worth stating plainly.

• Absence of evidence is not evidence of absence. Nothing here shows that FLGR-242 does not work as described. It shows that the question has not been answered in the published record, which is a different statement.
• The manufacturer’s claims may well be accurate. They are reported here as claims because they are unverified, not because they are implausible — each describes an achievable piece of protein engineering.
• Animal findings stay in their models. The follistatin muscle results come from transgenic mice and from gene delivery in mice and macaques. They describe those systems.
• Gene therapy is not protein administration. The two are repeatedly conflated in material about this compound, and they are not interchangeable.
• Nothing here concerns use in a person or animal. This guide gives no amounts, schedules or methods of use for any product.

Frequently asked questions

What is FLGR-242?

FLGR-242 is a supplier designation, not a molecule described in the scientific literature. It is marketed as a recombinant follistatin analog: a fragmented, modified form of Follistatin 344 fused to an albumin-binding peptide. Searches of PubMed, Europe PMC and ClinicalTrials.gov return no records under this name.

Is there any published research on FLGR-242?

No. As of November 2026 there is no published structural characterization, no preclinical animal study, no trial and no case report that names FLGR-242. The published literature it is associated with concerns follistatin generally, not this construct.

Is FLGR-242 the same as Follistatin 344?

No. Follistatin 344 is a defined, well-studied protein with a known sequence and a literature going back to 1987. FLGR-242 is a product name for a construct the manufacturer describes as derived from Follistatin 344 and fused to an albumin-binding peptide. The modified construct has not been independently characterized.

What does the albumin-binding part do?

Fusing a protein to a peptide that binds serum albumin is an established pharmacokinetic strategy in protein engineering: the bound complex clears more slowly than the free protein. That strategy is documented in the literature in general terms. No published measurement of this particular construct exists.

Why are follistatin gene-therapy results not evidence about FLGR-242?

Gene therapy delivers a gene so that tissue produces a protein continuously and locally. An injected protein is a different intervention with different distribution and duration. Results from follistatin gene-delivery studies in mice and macaques describe those systems and say nothing directly about an injected construct.

Does follistatin inhibit myostatin?

In laboratory studies, follistatin binds myostatin and blocks it from reaching its activin type IIB receptor. Transgenic mice engineered to overexpress follistatin in skeletal muscle showed muscle-mass increases comparable to myostatin-knockout mice. These are findings in engineered mice, not results for any administered material.

What is the difference between FLGR-242 and FLRG?

They are unrelated and easy to confuse. FLRG, also called FSTL3, is a genuine protein: a follistatin-related gene product that also binds activin. FLGR-242 is a product designation. A letter transposition turns one into the other, so check which is meant.

Is FLGR-242 FDA approved?

No. It is not an approved drug in any form, and no FDA review of it has taken place. It is sold as a research chemical. Patriot Labs supplies it strictly for in-vitro research and laboratory use, not for human or veterinary use.

References

1. Ueno, N., Ling, N., Ying, S.-Y., Esch, F., Shimasaki, S., & Guillemin, R. (1987). Isolation and partial characterization of follistatin: a single-chain Mr 35,000 monomeric protein that inhibits the release of follicle-stimulating hormone. Proceedings of the National Academy of Sciences, 84(23), 8282–8286. doi:10.1073/pnas.84.23.8282
2. Shimasaki, S., Koga, M., Esch, F., et al. (1988). Primary structure of the human follistatin precursor and its genomic organization. Proceedings of the National Academy of Sciences, 85(12), 4218–4222. doi:10.1073/pnas.85.12.4218
3. Thompson, T. B., Lerch, T. F., Cook, R. W., Woodruff, T. K., & Jardetzky, T. S. (2005). The structure of the follistatin:activin complex reveals antagonism of both type I and type II receptor binding. Developmental Cell, 9(4), 535–543. doi:10.1016/j.devcel.2005.09.008
4. McPherron, A. C., Lawler, A. M., & Lee, S.-J. (1997). Regulation of skeletal muscle mass in mice by a new TGF-β superfamily member. Nature, 387(6628), 83–90. doi:10.1038/387083a0
5. Lee, S.-J., & McPherron, A. C. (2001). Regulation of myostatin activity and muscle growth. Proceedings of the National Academy of Sciences, 98(16), 9306–9311. doi:10.1073/pnas.151270098
6. Dennis, M. S., Zhang, M., Meng, Y. G., Kadkhodayan, M., Kirchhofer, D., Combs, D., & Damico, L. A. (2002). Albumin binding as a general strategy for improving the pharmacokinetics of proteins. Journal of Biological Chemistry, 277(38), 35035–35043. doi:10.1074/jbc.M205854200
7. Kota, J., Handy, C. R., Haidet, A. M., et al. (2009). Follistatin gene delivery enhances muscle growth and strength in nonhuman primates. Science Translational Medicine, 1(6), 6ra15. doi:10.1126/scitranslmed.3000112
8. Haidet, A. M., Rizo, L., Handy, C., et al. (2008). Long-term enhancement of skeletal muscle mass and strength by single gene administration of myostatin inhibitors. Proceedings of the National Academy of Sciences, 105, 4318–4322.
9. Matzuk, M. M., Lu, N., Vogel, H., et al. (1995). Multiple defects and perinatal death in mice deficient in follistatin. Nature, 374, 360–363. doi:10.1038/374360a0

For related reading, see What Is Follistatin 344?, Recombinant vs Synthetic Peptides, Peptide Half-Life Extension and Understanding Peptide COA Testing.

All Patriot Labs products are sold strictly for in-vitro research and laboratory use only. Not for human or veterinary consumption. This guide is educational and describes the published research record surrounding follistatin and the claims made for a commercial follistatin analog; it is not medical advice, does not describe how to use any product, and makes no claim about outcomes in humans or animals. Gene-therapy studies are described as research history only; research-grade material is not an approved drug and is not what was used in those studies.